Načítá se...
Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors
Regorafenib is a multi-target tyrosine kinase inhibitor that has been approved for the treatment of metastatic colorectal cancer, advanced hepatocellular carcinoma, and metastatic gastrointestinal stromal tumors (GIST). Severe hepatobiliary toxicity has been reported in patients with colorectal canc...
Uloženo v:
| Vydáno v: | Mol Clin Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7523284/ https://ncbi.nlm.nih.gov/pubmed/33005406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2143 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|